Sheel Biotech Limited Announces Audited Financial Results for Fiscal Year 2026

Sheel Biotech Limited Announces Audited Financial Results for Fiscal Year 2026​

Sheel Biotech Limited announced the audited financial results for the year ended March 31, 2026, following its Board Meeting held on May 28, 2026. The company released the detailed financial reports, alongside the audit opinion from S S Mangla & Co LLP, Chartered Accountants.

The company maintains a presence in the biotech and agricultural sectors, focusing on Tissue Culture, Organic Farming, Planting & Landscaping, and Berry Cultivation.

Financial Highlights (FY 2026 vs FY 2025)​

The audited financial statements indicate substantial changes in the company's financial position and performance year over year.

Based on the comparison of the Balance Sheet figures (amounts in Rs. Lakhs), the total equity and liabilities for the year ended March 31, 2026, stood at Rs 14,578.43, up from Rs 11,136.36 in the previous fiscal year.

Profitability and Operational Performance​

The Profit and Loss statement for the year ended March 31, 2026, showed a Total Income of Rs 11,073.51 Lakhs, compared to Rs 10,227.08 Lakhs in the previous year. The company reported a Profit (Loss) for the Period of Rs 1,175.64 Lakhs, against Rs 1,075.54 Lakhs in the prior year.


Cash flow data reveals significant fluctuations in operating and financing activities. Cash and cash equivalents at the end of the year 2026 were reported at Rs 21,829 Lakhs, up from Rs 1,640 Lakhs at the end of the 2025 financial year.

Auditor's and Internal Control Findings​

The Statutory Auditor's Report provided an unqualified opinion, stating that the financial statements give a true and fair view of the Company's state of affairs and its profit and cash flows.

Regarding statutory compliance, the auditors reported that the company is regular in depositing undisputed statutory dues, and there were no outstanding statutory dues as on March 31, 2026, for a period exceeding six months. Furthermore, the company confirmed that no material uncertainty exists regarding its ability to meet its liabilities falling due within one year of the balance sheet date.

The assessment of internal financial controls also found the Company to have an adequate internal financial controls system over financial reporting, and that these controls were operating effectively as at March 31, 2026.

In terms of capital raises, the audit noted that the company raised Rs 34.02 crore through an Initial Public Offer (IPO) during the year ended March 31, 2026. Out of the funds raised, Rs 31.28 crore was applied for the purpose for which the funds were raised, with the remaining Rs 2.74 crore remaining unutilised.

SHEEL Stock Price Movement​

On Wednesday, shares of Sheel Biotech Limited gained 4.97%, settling at ₹45.4 as the equity closed significantly higher. The stock traded on 6,000 shares, achieving an intraday high of ₹45.45.